Prashanthi Vemuri

Jan 16, 2025 | nature.com | Farwa Ali |Michelle M. Mielke |Clifford R. Jack |David S. Knopman |Prashanthi Vemuri |Ronald Petersen | +1 more

AbstractDeclining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181). In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer’s Disease pathology are associated with worse gait performance.

Sep 20, 2024 | nature.com | Shannon L. Risacher |Paula J Bice |Jared Brosch |Kelley Faber |Martin R Farlow |Tatiana Foroud | +29 more

AbstractDetermining the genetic architecture of Alzheimer’s disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron emission tomography in 3046 participants from 12 independent studies. The CYP1B1-RMDN2 locus is associated with tau deposition.

May 29, 2023 | nature.com | Emily S. Lundt |Christopher Schwarz |Matthew L. Senjem |Robert Reid |David S. Knopman |Prashanthi Vemuri | +3 more

In this work, we used an AFT model to study the association of individual adjustments in timing of AD and CVD biomarker progression. These findings are important in informing the proposed relationships between AD (defined as an accumulation of pathological aggregated amyloid and tau proteins) and small vessel cerebrovascular disease. The individual adjustments of AD biomarkers (amyloid and tau PET) and established CVD biomarkers (WMH and FA GCC) showed weak to no association.